The Washington DC-based Sabin Vaccine Institute today announced it is receiving an additional $21.8 million under an existing contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA).
These BARDA funds will advance the development of a vaccine against Marburg virus disease.
Currently, there are no U.S. FDA-approved vaccines for Marburg disease.
The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial.
In 2019, BARDA awarded Sabin a multi-year contract valued at $128 million to further the development of vaccines against Marburg and Ebola Sudan.
Marburg, a virus related to Ebola Zaire, is among the world’s deadliest viruses, resulting in the death of approximately half the people the virus infects.
The latest BARDA funds enable Sabin to conduct a randomized, blinded, placebo-controlled clinical trial among adults in the USA and advance non-clinical vaccine dosing studies.
The Phase 2 clinical trial in the USA will begin after Sabin has initiated a same-stage trial in Africa, currently scheduled for 2023.
“Beginning Phase 2 clinical trials for the Marburg vaccine is a pivotal milestone for us, and we appreciate BARDA’s continued confidence in our work and support for this critical next step,” says Sabin’s CEO Amy Finan, in a press release issued on September 13, 2022.
At Least 2 More Pestilences Warning 3/10/22 @ 5:15AM (Prophetic Words and Visions from my Lovely Jesus)
The Tribulation is commencing..
Please repent, carry your cross daily and accept the free gift of Jesus Christ’s Death on the Cross for payment for your sins.
#Yahweh #Yeshua #HolySpirit #LordAlmighty #SovereignLord #Nameaboveallnames #TheWay #TheTruth #TheLife #TheGate #Heaven #KingdomofHeaven #Saved #Glorified #Endtimes #LastDays #FeastofTrumpets #markofthebeast #verseoftheday #birthpains #Judgement #Christian #Christianity #hope #love #Jesus #Christ
Leave a Reply